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Introduction {#sec001}
============

Diastolic dysfunction is an important cause of heart failure (HF) with preserved ejection fraction (pEF) in diabetes, overall in type 2 diabetes \[[@pone.0209794.ref001]\]. Considering the worldwide epidemic increase in type 2 diabetes incidence along with complications \[[@pone.0209794.ref002]\], it is presumable that this cardiac condition will become a major public health burden \[[@pone.0209794.ref003]\]. Epidemiologic studies have shown that different grades of diastolic dysfunction may be detected in patients with type 2 diabetes \[[@pone.0209794.ref004]--[@pone.0209794.ref006]\].

Left ventricular (LV) end-diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) are frequent measures used to assess LV diastolic function \[[@pone.0209794.ref007]\]. In this respect, echocardiography is the mainstay for the noninvasive evaluation of diastolic function \[[@pone.0209794.ref007]\]. Early mitral annular velocity (e') obtained by tissue doppler imaging estimates LV myocardial relaxation activity: e' less than 10 (lateral annular location) and e' less than 7 cm/sec (septal annular location) may suggest impaired myocardial relaxation \[[@pone.0209794.ref007]\].

With mitral early filling velocity E, the ratio E/e' is largely used to estimate the left ventricular filling pressure (LVFP) and its use is recommended by the echocardiographic Societies to evaluate diastolic function and HFpEF \[[@pone.0209794.ref007]--[@pone.0209794.ref008]\].

Despite a large use of E/e' ratio, the extent of its alteration in type 2 diabetes without cardiovascular complications is still elusive.

In the present meta-analysis we summarize the averaged E/e' ratio mean difference between subjects affected by type2 diabetes without cardiovascular complications and control subjects. We also summarize the averaged E/e' ratio mean difference in various clinical conditions in patients with type 2 diabetes that may confound this relationship.

Materials and methods {#sec002}
=====================

We conducted this systematic review and meta-analysis in accordance with the PRISMA guidelines \[[@pone.0209794.ref009]\] and registered our project with the international prospective register of systematic reviews (PROSPERO---number CRD42018093585)

Search strategy {#sec003}
---------------

Four investigators (G.Z., A.M., M.D., G.T.) independently searched PubMed, Web of Science and Scopus for pertinent articles. Furthermore, the investigators scanned references of retrieved articles and pertinent reviews to detect further studies.

As reported in [Fig 1](#pone.0209794.g001){ref-type="fig"}, we performed two kinds of researches: 1) more liberal using generic items ('Diabetes', 'Diastolic dysfunction', 'Controls') and ('Diabetes', 'Tissue doppler', 'Controls') that retrieved 760 studies; 2) using more restrictive items: ('Diabetes', 'Tissue Doppler velocity', 'Controls') and ('Diabetes', 'e/e', 'Controls') that retrieved 32 studies.

![The PRISMA flowchart of the systematic search and quantitative synthesis.](pone.0209794.g001){#pone.0209794.g001}

The PubMed search was carried out by using isolated terms, not phrases nor Boolean operators in order to retrieved the larger number of references (free word searching). The terms were written directly in the search mask. Limits: only articles published in English were considered, we only included studies reporting data obtained by transthoracic echocardiography. Duplicates were manually searched. The last search update was on January 20, 2018.

Eligibility criteria and identification of study {#sec004}
------------------------------------------------

Definition and diagnosis of diabetes has been the same since 2010 \[[@pone.0209794.ref010]\]. Studies were included if they provided the mean E/e' ratio (averaged TDI e' values of lateral and septal annular region), comparing values in type 2 diabetes patients and in control subjects. Inclusion criteria were cross-sectional studies reporting the mean E/e' ratio in adult patients with type 2 diabetes without any previous cardiovascular diseases except non complicated hypertension and matched or unmatched controls subjects. Exclusion criteria were studies reporting either septal or lateral annular e' measures, studies on those under 18 years and studies on subjects with known cardiovascular diseases, including atrial fibrillation.

Study selection and data extraction {#sec005}
-----------------------------------

The four authors reviewed the findings of the electronic search and selected the articles potentially relevant to the topic of interest. The identified articles were downloaded and then assessed against the eligibility criteria. Any discrepancy in an author's opinion on the inclusion of an article was resolved by consensus and/or by involving the other authors (C.B., A.R., E.B.). Two reviewers (G.Z., M.D.) independently extracted the data from each study, which were recorded into a pre-defined collection sheet. Data extracted from each study included the number of type 2 diabetes patients and controls, the mean of averaged E/e' ratio of both groups and the standard deviations of both groups along with other data ([Table 1](#pone.0209794.t001){ref-type="table"}).

10.1371/journal.pone.0209794.t001

###### Characteristics of enrolled case-control studies of averaged E/e' ratio in type 2 diabetes patients compared to non-diabetic controls.

OP: outpatient; CP: consecutive patient; H: healthy control. NOS: Newcastle-Ottawa scale. Case: type 2 diabetic patients; Control: healthy non-diabetic controls.

![](pone.0209794.t001){#pone.0209794.t001g}

                  Case      Control                                                                                                                                      
  --------------- --------- --------- -------- ----------- ------- ------------ ---- -------- ---------- --------- ----------- --------------------------------- --- --- -----
  Tayebjee MN     UK        OP        54.00    68±5        43/12   10.9±1.3     H    31.00    66±5       18/13     8.1±2       age and sex                       6   1   7.3
  Govind SC.      Sweden    CP        31.00    49.2±6.3    20/11   10.8±2.4     H    13.00    49.7±5.4   8/5       7.9±0.7     age. LV size and ECG parameters   6   0   8.1
  Yazici M.       Turkey    OP        72.00    49.1±9.8    36/36   6.2±3.8      H    50.00    46.1±9.8   17/33     6.2±2.8     no                                6   0   8.3
  Mogelvang R.    Denmark   OP        65.00    68±11       42/13   12.7±1.5     NA   533.00   51±14      233/300   9±1.3       no                                6   0   
  Andersson CH.   Denmark   OP        31.00    58±12       16/15   9.9±5.8      H    31.00    58±12      16/15     7.0±1.6     age.sex.hypertension              8   1   
  Tayyareci Y.    Turkey    CP        60.00    58.2±11.3   21/39   8±1.6        H    40.00    57.4±8.1   12/28     4.8±1.4     age and sex                       7   0   7.6
  Ernande L.      France    OP        114.00   52±4.5      60/45   10.9±3.6     H    88.00    51.7±2.6   30/58     7.7±1.7     age and sex                       7   1   7.7
  Ceyhan K.       Turkey    CP        48.00    56±11       28/20   11.5±3.0     H    60.00    56±11      32/28     9.8±2.2     age and sex                       7   0   7.8
  çiftel S.       Turkey    CP        21.00    54.1±5.7    11/10   4.9±1.9      H    40.00    53±6.8     17/23     5.6±1.9     no                                5   0   9.4
  Conte L.        Italy     OP        44.00    60.9±6.6    23/21   9.3±3.4      H    24.00    58.4±9.4   13/11     7±1.6       no                                4   1   7.3
  Erdogan D.      Turkey    NA        45.00    51.6±7.2    19/26   10.25±3.11   NA   43.00    50.4±8.5   18/25     9.05±2.41   no                                5   1   7.4
  Atas J.         Turkey    CP        40.00    50.5±7.3            7.7±2.3      H    40.00    48.4±6.7             6.2±1.3     age and sex                       7   0   7.3
  Bakirci EM.     Turkey    CP        132.00   54.5±9.6    76/56   8.9±2.8      H    80.00    53.2±9.0   50/30     8.6±2.5     age and sex                       7   0   8.4
  Loncarevic B    Serbia    CP        70.00    54.8±7.7    38/32   10.11±3.27   H    80.00    54.8±4.9   44/36     7.40±1.42   age and sex                       6   0   6.7
  Vukomovic V.    Serbia    CP        50.00    55±7        26/24   9.4±3        H    40.00    50±9       12/18     7.0±1.8     no                                5   0   7.3

Quality assessment of study design {#sec006}
----------------------------------

Methodological quality of selected cross-sectional studies was estimated using the Newcastle-Ottawa scale (NOS). The NOS explores risk of bias in three different domains: selection, comparability and outcome/exposure. A maximum cumulative score of 9 (stars) points can be obtained: four stars for selection, two stars for comparability and three stars for outcome/exposure. Studies were classified as high-risk (1--3 points), intermediate (4--5 points) or low-risk of bias (6--9 points) \[[@pone.0209794.ref011]\]. Three authors made the NOS score independently and a final agreement was reached ([S2 Table](#pone.0209794.s002){ref-type="supplementary-material"}). The authors'judgments about each domain of the Newcastle-Ottawa Scale is presented in [S3 Table](#pone.0209794.s003){ref-type="supplementary-material"}, while the Cochrane Risk of Bias Study-by-Study in [S4 Table](#pone.0209794.s004){ref-type="supplementary-material"}.

Analysis {#sec007}
--------

The analysis investigated the differences between averaged E/e' ratio between patients with type 2 diabetes and non-diabetic controls. We further conducted a subgroup/sensitivity analyses to explore the possible sources of heterogeneity.

Statistical analysis {#sec008}
--------------------

Mean values and standard deviation (SD) of the variables of interest were collected for the analysis. If data were reported only as median and interquartile range (none of the final studies included), published and online Cochrane's recommendations to approximate the values of mean and SD can be followed \[[@pone.0209794.ref012]\]. One study reported the geometric mean, however as the measure of interest was the difference of the means, we included this difference measure in the analysis.

The weighted mean differences (WMDs) were used to compare the averaged E/e' ratio between the case and control subjects. The pooled data were calculated by using a random-effect model to achieve a more conservative assessment. Statistical heterogeneity was estimated using Cochrane's Q test and the I^2^ statistics. Heterogeneity was likely if Q\>df (degree of freedom), and confirmed if P ≤ 0.10. Quantification of heterogeneity was performed by using I^2^ statistics. The degree of heterogeneity was defined as none, low, moderate or high according to I^2^ values of 0--24.9%, 25--49.9%, 50--74.9% and \> 75%, respectively. Publication bias was qualitatively assessed by the visual inspection of funnel plot asymmetry of the MD against their standard errors. The Egger's regression asymmetry was also calculated and a P \<0.05 was considered to be suggestive of a statistically significant publication bias. Meta-analysis was performed with R metaphor.

This study was conducted in compliance with the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@pone.0209794.ref013]--[@pone.0209794.ref014]\]. A p value less than 0.05 was considered as statistically significant.

Results {#sec009}
=======

The literature search produced 32 titles for the restrictive search strategy and 760 for the more liberal search approach. No additional articles were found by an independent search. All articles were screened yielding 40 studies as potentially relevant and full-text was retrieved. Twenty four studies were excluded: thus the sixteen remaining papers were selected for the qualitative synthesis, while fifteen were selected for the quantitative synthesis. The search on Embase and Scopus did not add further evidence to the Medline findings.

Therefore, 15 studies included in the meta-analysis provided transthoracic echocardiographic data on TDI values, in particular they provided results on averaged E/e' ratio.

The PRISMA flowchart of our systematic search and quantitative synthesis is reported in [Fig 1](#pone.0209794.g001){ref-type="fig"}. The characteristics of the studies included are summarized in [Table 1](#pone.0209794.t001){ref-type="table"} \[[@pone.0209794.ref015]--[@pone.0209794.ref029]\].

Fifteen cross sectional observational studies provided values of the averaged E/e' ratio between patients with type 2 diabetes (n = 877) and non-diabetic controls (n = 1193). The WMDs forest plot of this analysis is shown in [Fig 2](#pone.0209794.g002){ref-type="fig"}. Overall, type 2 diabetes patients without cardiovascular diseases exhibited a significantly higher averaged E/e' ratio (WMD 2.02; 95% CI 1.35, 2.70; p\<0.001, [Fig 2](#pone.0209794.g002){ref-type="fig"}) with high heterogeneity (I^2^ = 89.9%; p \< 0.001). Considering the significant heterogeneity among the studies, we conducted subgroups/sensitivity analyses. The region, the selection of controls (matching vs not matching), presence of non-complicated hypertension, and glycemic control (HbA1c ≤ 7.3% vs HbA1c \> 7.3%) may have influenced the summary combination, therefore we performed subgroups analyses according to these factors. The weighted forest plots of these analyses are shown in [Fig 3](#pone.0209794.g003){ref-type="fig"}. According to the region, the studies were divided in two subgroups and higher heterogeneity was found in studies from Serbia and Turkey (I^2^ = 88.5%; p \< 0.001). The overall WMD was 3.12 (95% CI 2.65, 3.59) in the west European region and 1.40 (95% CI 0.53, 2.16) in Serbia and Turkey region. High heterogeneity was found independently of controls matching. The not matching subgroup presented I^2^ = 92.7% (p \< 0.001) while the matching subgroup had I^2^ = 83.0% (p \< 0.001). The presence of non-complicated hypertension was associated with a lower heterogeneity (I^2^ = 56.2%; p = 0.072) compared to the absence of hypertension (I^2^ = 93.2%; p \< 0.001). Moreover, the WMD was 2.52 (95% CI 1.79, 3.24) when non-complicated hypertension was present and 1.81 (95% CI 0.88, 2.73) in the absence of hypertension.

![The Forest plot of the weighted mean difference (WMD) of E/e' ratio with 95% C.I. of the included studies that compared averaged E/e' between patients with and without diabetes.\
A positive value signifies that E/e' is higher in patients with diabetes.](pone.0209794.g002){#pone.0209794.g002}

![The Forest plot of the WMD with 95% C.I. of the subgroup analyses: Panel A, region; panel B, matching; panel C, hypertension; panel D, glycemic control.\
A positive value signifies that E/e' is higher in patients with diabetes.](pone.0209794.g003){#pone.0209794.g003}

Substantial low heterogeneity was found in the subgroup of studies with low mean HbA1c (≤ 7.3%) with I^2^ = 39.7% (p \< 0.177) respect to the studies with higher mean HbA1c (\> 7.3%) with I^2^ = 91.8% (p \< 0.001). The HbA1c was chosen because it was the median value of the means. The WMD was 2.34 (95% CI 1.82, 2.85) in the subgroup with better glycemic control and 1.50 (95% CI 0.43, 2.57) in the worse glycemic control subgroup. [S1 Table](#pone.0209794.s001){ref-type="supplementary-material"} shows the subgroups/sensitivity analyses respect to the number of participants to each study and to the NOS score. The overall effect was more stable when studies included more than 45 subjects and the NOS score was above 6.

None of the studies ranked between 1--3 NOS score, four studies (26%) were between 4--5 while the majority of studies were above 6 NOS score. Visual inspection of the funnel plot ([Fig 4](#pone.0209794.g004){ref-type="fig"}) did not identify substantial asymmetry and the Egger test for funnel plot asymmetry showed a p value of 0.36.

![The Funnel plot analysis of the studies included in the analysis.](pone.0209794.g004){#pone.0209794.g004}

Discussion {#sec010}
==========

Our meta-analysis investigated the WMD of averaged E/e' ratio between patients with type 2 diabetes without cardiovascular complications and non-diabetic controls. Care was taken in selecting studies that clearly reported that included subjects were free of cardiovascular complications, but non complicated hypertension.

We found a significantly higher averaged E/e' ratio in patients with type 2 diabetes. These findings may suggest the presence of LVDD in type 2 diabetes patients in the absence of significant cardiovascular complications and they were consistent either in subjects with and without non complicated hypertension or good and bad glycemic control. Thus, the results of this meta-analysis seems to indicate a possible direct detrimental effect of T2DM on the diastolic performance of myocardium.

Diastolic alterations may be a precocious phenomenon of the diabetic heart: indicated as diabetic cardiomyopathy \[[@pone.0209794.ref030]\].

Heart failure, especially HFpEF, and type 2 diabetes are frequently found associated in the same patient \[[@pone.0209794.ref031]--[@pone.0209794.ref032]\]. The coexistence of the two diseases is associated with a more severe clinical status and the prognosis is encumbered by an increased risk of all-cause and cardiovascular mortality \[[@pone.0209794.ref033]\]. We excluded subjects with cardiovascular diseases, that are responsible for most of the case of HF in diabetes. The other main cause of HF is arterial hypertension, that in our study was considered in the subgroups/sensitivity analyses. Therefore, after the exclusion of the main causes, HF may be the consequence of T2DM related-processes \[[@pone.0209794.ref034]\]. Major mechanisms of myocardial alteration in T2DM are insulin resistance/hyperinsulinemia and pre-diabetic conditions, such as obesity, dysglycemia and others. Hyperinsulinemia and dysglycemia may be present years or even decades before overt diabetes, likely contributing to myocardial dysfunction during this period \[[@pone.0209794.ref035]\]. In fact, left ventricular diastolic dysfunction may be detected in as many as about 75% of T2DM patients. Moreover, according to demographic characteristics of these patients, that may include younger age, normal blood pressure and optimal glycemic control, it can be supposed that left ventricular dysfunction may develop early in the course of the disease \[[@pone.0209794.ref001], [@pone.0209794.ref036]--[@pone.0209794.ref037]\].

Numerous metabolic abnormalities, commonly found in diabetes, may be detrimental to left ventricular diastolic function. Among these metabolic abnormalities are to be underlined for their importance nonenzymatic glycation of proteins, lipotoxicity and microvascular rarefication: all these abnormalities eventually lead to apoptosis and fibrosis \[[@pone.0209794.ref034]\].

One simple clinical approach to detect myocardial dysfunction is transthoracic echocardiography with TDI investigation. In particular, the E/e' ratio, that estimates the left ventricular filling pressure, is one of the most important parameters to detect diastolic dysfunction in subjects with pEF. When E/e' ratio increased at rest, it associates with adverse outcomes \[[@pone.0209794.ref038]\].

E/e' ratio has been shown to possess a good prognostic impact on different outcomes such as all-cause mortality, cardiovascular death and heart failure hospitalization in various studies \[[@pone.0209794.ref039]--[@pone.0209794.ref040]\]. Furthermore, a 4-year longitudinal study showed that progressive worsening in E/e' ratio was associated with an increased incidence of heart failure \[[@pone.0209794.ref041]\]. We believed that the novelty of our study are: the care of the selected patients thus proving that E/e' may represent an early alteration, and second that patients with normal blood pressure and higher level of HbA1c showed a higher variability in the estimates. Therefore, even patients in good metabolic control may develop alteration in E/e' ratio and hypertension may contribute to this alteration. The results of our meta-analysis are clinically relevant as they indicate that a single a reproducible parameter may be precociously altered. However, it should be remembered that we do not have cutoff levels of averaged E/e' under the value of 14. Future studies are needed to evaluate the linear prognostic value of this parameter.

An advance in our knowledge is the routine measure of E/e' ratio, as marker of increased LV filling pressure, given the high prevalence of hypertension and heart failure in T2DM. Screening HF is important since its two early phases, stage A (HF risk factors), and stage B (characterized by structural or functional evidence of myocardial disease), are asymptomatic \[[@pone.0209794.ref042]\]. It is of note that in these two HF stages T2DM is cited and therapy, with protective effect, has an established indication in the prevention of incident HF. Thus, echocardiography is a test that may potentially influence therapeutic decision making.

Sources of heterogeneity {#sec011}
------------------------

In the present meta-analysis there was a substantial heterogeneity among the publications (I^2^ \> 50%). Several factors might explain the heterogeneity, such as the characteristics of both diabetes and controls populations. Another possible factor of heterogeneity is the different echocardiographic equipment in the diverse centers. Moreover, different factors, such as age, glycemic control, hypertension may be associated with variations of E/e' ratio, for this reason we performed subgroups analyses to take into account these possible confounders. As shown in [Fig 2](#pone.0209794.g002){ref-type="fig"}, region, glycemic control and hypertension can decrease the heterogeneity.

Study strengths and limitations {#sec012}
-------------------------------

The major strength of this study is the comprehensiveness of the literature retrieval and review. All studies included subjects with no cardiovascular diseases. We also included important clinical factors such as glycemic control and hypertension. The data of the studies are as complete as possible, and we included only case-control studies with a fair representation of recent publications. Moreover, we performed subgroups analyses to further illustrate the result of this topic. And finally, as far as we know the present is the most comprehensive and updated synthesis of E/e' ratio in patients with type 2 diabetes.

This study has limitations. The matching between cases and controls was not consistent in all studies. The inclusion and exclusion criteria slightly differed among studies. The clinical characteristics of T2DM patients were not complete in some study. Diabetes duration was not reported in many studies. Heterogeneity is substantial among studies even in the subgroup analyses. Despite of all the limitations, the results of this analysis are consistent.

Conclusions {#sec013}
===========

In conclusion, our assessment suggests that averaged E/e' ratio is consistently increased in type 2 diabetes patients compared to non-diabetic controls in the absence of cardiovascular diseases and complicated hypertension. This alteration may be a precocious diastolic alteration of the diabetic cardiomyopathy. Nevertheless, the prognostic role of E/e' should be considered with caution. Future studies relating outcomes to E/e' in diabetes may clarify the real prognostic importance of this parameter.
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HbA1c

:   glycated hemoglobin

HF

:   heart failure

LV

:   left ventricle

LVDD

:   left ventricular diastolic dysfunction

LVEDP

:   left ventricular end-diastolic pressure

LVEDV

:   left ventricular end diastolic volume

LVEF

:   left ventricular ejection fraction

LVFP

:   left ventricular filling pressure

NOS

:   Newcastle-Ottawa scale

PCWP

:   pulmonary capillary wedge pressure

pEF

:   preserved ejection fraction

T2DM

:   type 2 diabetes mellitus

TDI

:   tissue Doppler imaging

WMD

:   weighted mean difference
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